Aker Biomarine AS (AKBM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aker Biomarine AS (AKBM) has a cash flow conversion efficiency ratio of -0.046x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-6.90 Million ≈ $-726.08K USD) by net assets (Nkr149.50 Million ≈ $15.73 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Aker Biomarine AS worth for the company's overall valuation and market capitalisation.
Aker Biomarine AS - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Aker Biomarine AS's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Aker Biomarine AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aker Biomarine AS ranked by their cash flow conversion efficiency. Explore Aker Biomarine AS (AKBM) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nanjing Xinjiekou Department Store Co Ltd
SHG:600682
|
0.009x |
|
Hubei Biocause Pharmaceutical
SHE:000627
|
0.008x |
|
Lelon Electronics Corp
TW:2472
|
0.039x |
|
Yantai Changyu Pioneer Wine Co Ltd
SHE:000869
|
0.011x |
|
Yibin Tianyuan Group Co Ltd
SHE:002386
|
0.021x |
|
Kunshan Guoli Electronic Technology Co Ltd
SHG:688103
|
0.012x |
|
Guangdong Haomei New Material Co Lt
SHE:002988
|
0.017x |
|
Tianjin Ringpu Bio Tech
SHE:300119
|
0.020x |
Annual Cash Flow Conversion Efficiency for Aker Biomarine AS (2016–2024)
The table below shows the annual cash flow conversion efficiency of Aker Biomarine AS from 2016 to 2024. View Aker Biomarine AS share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Nkr173.90 Million ≈ $18.30 Million |
Nkr12.20 Million ≈ $1.28 Million |
0.070x | -45.76% |
| 2023-12-31 | Nkr366.50 Million ≈ $38.57 Million |
Nkr47.40 Million ≈ $4.99 Million |
0.129x | +224.36% |
| 2022-12-31 | Nkr378.70 Million ≈ $39.85 Million |
Nkr15.10 Million ≈ $1.59 Million |
0.040x | +1925.77% |
| 2021-12-31 | Nkr370.37 Million ≈ $38.97 Million |
Nkr729.00K ≈ $76.71K |
0.002x | +101.44% |
| 2020-12-31 | Nkr373.17 Million ≈ $39.27 Million |
Nkr-51.04 Million ≈ $-5.37 Million |
-0.137x | -271.77% |
| 2019-12-31 | Nkr154.55 Million ≈ $16.26 Million |
Nkr12.31 Million ≈ $1.30 Million |
0.080x | +80.36% |
| 2018-12-31 | Nkr178.81 Million ≈ $18.82 Million |
Nkr7.89 Million ≈ $830.78K |
0.044x | -71.46% |
| 2017-12-31 | Nkr59.30 Million ≈ $6.24 Million |
Nkr9.17 Million ≈ $965.37K |
0.155x | -45.15% |
| 2016-12-31 | Nkr74.03 Million ≈ $7.79 Million |
Nkr20.88 Million ≈ $2.20 Million |
0.282x | -- |
About Aker Biomarine AS
Aker BioMarine ASA, a biotech innovator, develops and supplies krill-derived products for consumer health and wellness worldwide. It operates through three segments: Human Health Ingredients (HHI), Consumer Health Products, and Emerging Business. The Human Health Ingredients segment sells B2B krill oil supplements for humans under the Superba Krill brand; supplements for brain health under the LY… Read more